Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns “Hold” Rating from Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reissued by Needham & Company LLC in a note issued to investors on Friday,Benzinga reports.

A number of other brokerages have also issued reports on LXRX. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Trading Up 12.8 %

Shares of NASDAQ:LXRX traded up $0.10 during trading on Friday, reaching $0.87. The stock had a trading volume of 6,844,754 shares, compared to its average volume of 3,491,705. The stock has a market cap of $214.28 million, a P/E ratio of -1.18 and a beta of 1.24. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a fifty-two week low of $0.73 and a fifty-two week high of $3.73. The business has a fifty day moving average price of $1.55 and a 200-day moving average price of $1.71.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $3.14 million. During the same quarter in the previous year, the business posted ($0.21) EPS. As a group, analysts anticipate that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LXRX. Compagnie Lombard Odier SCmA boosted its position in shares of Lexicon Pharmaceuticals by 6.4% during the 3rd quarter. Compagnie Lombard Odier SCmA now owns 100,000 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 6,000 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Lexicon Pharmaceuticals by 116.1% in the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 12,225 shares during the period. BNP Paribas Financial Markets lifted its stake in Lexicon Pharmaceuticals by 71.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 13,246 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Lexicon Pharmaceuticals by 44.5% during the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 13,972 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Lexicon Pharmaceuticals by 40.5% during the second quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 14,411 shares during the period. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.